



Catalyze Preclinical Application Version.4 2022.10.19

**Applicant Last Name:** \_\_\_\_\_

**Project Title:** \_\_\_\_\_

**Date of Submission:** \_\_\_\_\_

### Section 1: Contact Information

*Provide contact information for the principal investigator and the corresponding organizational representative authorized to submit proposals on the PI's behalf, if not the PI.*

1. Project Title: \_\_\_\_\_
2. Is this a resubmission of a proposal for a project for which support was previously sought under Catalyze?  Yes  No
3. Principal Investigator (Last Name, First Name): \_\_\_\_\_
4. Organization: \_\_\_\_\_
5. Title: \_\_\_\_\_
6. Department (or Discipline): \_\_\_\_\_
7. Street Address: \_\_\_\_\_
8. City: \_\_\_\_\_
9. State: \_\_\_\_\_
10. Zip code: \_\_\_\_\_
11. PI email address: \_\_\_\_\_
12. PI telephone number: \_\_\_\_\_
13. Name and contact information for corresponding organizational representative, if not the PI:  
\_\_\_\_\_
14. How did you learn about Catalyze? (Select all that apply):

<input type="checkbox"/> NIH/NHLBI website	<input type="checkbox"/> My technology transfer office
<input type="checkbox"/> NHLBI Catalyze website	<input type="checkbox"/> Scientific conference or news article
<input type="checkbox"/> NIH Translational Program(s) (e.g., REACH, NCAI, SMARTT, CADET II)	<input type="checkbox"/> NIH Program Officer
<input type="checkbox"/> Catalyze event	<input type="checkbox"/> Other (Please specify): _____
<input type="checkbox"/> My institution/department	



## Section 2: PI Demographic Profile

***Your responses to the following questions allow the Catalyze Coordinating Center to better understand the demographic profile of investigators interested in Catalyze award programs. Your responses to these questions have no influence on proposal selection and will not be shared with reviewers.***

15. Position or title: \_\_\_\_\_

16. Terminal Degree: \_\_\_\_\_

17. Year of Terminal Degree (or Expected Completion Year): \_\_\_\_\_

18. Gender: Do you describe yourself as a man, a woman, or in some other way?

Man       Woman       Non-binary       Prefer not to say

19. Race: What is your race? Please select all that apply

American Indian or Alaska Native       White  
 Asian       Other  
 Black or African American       Prefer not to say  
 Native Hawaiian or Other Pacific Islander

20. Ethnicity: Do you describe yourself as Hispanic or Latino?

Hispanic or Latino (A person of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race)  
 Not Hispanic or Latino  
 Prefer not to say

21. Disability Status: Are you disabled?

Disabled       Not disabled       Prefer not to say

22. Has your professional experience to-date been characterized by any of the following? Select all that apply:

Been granted a copyright, patent, or trademark  
 Licensed your technology to another party  
 Applied for funding from a translational research, proof-of-concept, or commercialization support program—other than Catalyze  
 Received funding from a translational research, proof-of-concept, or commercialization support program—other than Catalyze  
 Founded a start-up company



### Section 3: Technology Profile

*Provide the following information about the project for which Catalyze assistance is sought.*

23. Disease area (select all that apply):

- |   |                                |
|---|--------------------------------|
| <input type="checkbox"/> Blood                | <input type="checkbox"/> Lung  |
| <input type="checkbox"/> Cardiovascular/Heart | <input type="checkbox"/> Sleep |

24. Technology type (select one):

- |  |  |
|--|--|
| <input type="checkbox"/> Biologic            | <input type="checkbox"/> Medical device                |
| <input type="checkbox"/> Drug                | <input type="checkbox"/> Health information technology |
| <input type="checkbox"/> Combination product | <input type="checkbox"/> Research tool                 |
| <input type="checkbox"/> In vitro diagnostic |  |

25. What type of support is being requested from the Preclinical Catalyze Program?

- Preclinical Studies and/or Chemistry Manufacturing and Controls Work

Please describe (50-word limit): \_\_\_\_\_

- Preclinical Catalyze Coordinating Center Assistance (regulatory guidance and documentation, gap analysis)

Please describe (50-word limit): \_\_\_\_\_

26. What is the specific technology or product (50-word limit)? \_\_\_\_\_

27. What is the indication (50-word limit)? \_\_\_\_\_

28. If the project is for a therapeutic, what is the target (e.g., Kinase, Receptor, Protein, Mechanism of Action) for the product (50-word limit)?  
\_\_\_\_\_

29. In two or three sentences, what is the technical goal of the project (50-word limit)?  
\_\_\_\_\_

30. Indicate the level of intellectual property protection for this technology (select all that apply):

- No invention disclosure filed with technology transfer office (or equivalent)
- Invention disclosure filed with TTO (or equivalent)
- A patent application has been submitted
- A trademark has been registered
- A copyright has been granted
- None of the above



Catalyze Preclinical Application Version.4 2022.10.19

31. Do you have efficacy data in a relevant animal model by the route of administration to be used in the clinic?

Yes  No  Not applicable

Other (50-word limit): \_\_\_\_\_

32. For device and diagnostics, have you confirmed conceptualization and proof of concept via prototyping of all or part of the conceived product with supporting data (i.e., animal or known-sample studies)? and documentation. Has a Design History File been created?

If Yes, please describe (50-word limit):

\_\_\_\_\_  
 No

Not Applicable

Other (50-word limit):

\_\_\_\_\_  
33. **Project Description.** In 1,000 words or less, please provide an overall description of your project. Include the project purpose or objective, therapeutic relevance to the NHLBI mission, a description of preliminary studies, a concise description of the studies you are proposing, the unmet market need or innovation to potentially change standard of care, and commercialization path.

\_\_\_\_\_  
34. Explain why support for this project is sought from NHLBI and the Catalyze program as opposed to private sector or other sources of support.

#### Section 4: Prior Technology Development Support

*The following questions request information about any funding and translational program support history for the technology to be developed under the proposed project. Please provide information about NIH and non-NIH support. Please also indicate whether the principal investigator and/or the technology have been supported by any NIH translational programs.*



Catalyze Preclinical Application Version.4 2022.10.19

35. Were any earlier translational or product development stages supported by any of the following NIH-sponsored translational programs? (select all that apply):

- NCAI (B-BIC, UC CAI, or NCAI-CC)
- REACH 2015 (UofL ExCITE, MN-REACH, or LIBH)
- REACH 2019 (KYNETIC, MBarC, ROI, CO-SPARK, or WE-REACH)
- NIGMS STTR Tech Transfer Hubs (ASCEND, DRIVEN, SHARP Hub, Southeast Xlerator Network)
- tPPG
- POCTRN (CAPCat)
- VITA
- CADET II
- Excellence in Hemoglobinopathies
- Molecular Imaging of the Lung
- Thrombotic and Hemostatic Centers
- Pulmonary Vascular-RV Axis
- Preclinical GTRP
- Preclinical PACT
- Preclinical SMARTT
- Transformative Platforms
- Bioengineering for HLBS
- Large Animal Blood Disease Core
- None of the above
- Other (Please provide name of NIH opportunity or program): \_\_\_\_\_